Levine Media Group provides content, research, and analysis to life sciences clients. We write about science for lawyers and the law for scientists.
Levine Media Group specializes in taking complex ideas at the intersection of business, policy, and science and making them accessible to targeted audiences. We convince policy makers, excite investors, motivate employees, reach out to patients, and provide life sciences companies with strategic content to achieve their goals. We tell the stories of the people, companies, and organizations shaping
the life sciences. We bring journalists’ sensibilities to creating strategic communications for life sciences companies. Through our network of experienced writers, editors, researchers, and graphic designers, we take the content we create and deliver it in whatever way meets the needs of our clients from print and digital publications, webcasts, podcasts, conferences, road shows, or other formats. We can produce a wide range of content to meet the needs of our clients including op-eds and articles, white papers, reports, or recurring publications, and more. To see what we can do for you, just ask [email protected].
Neil McFarlane, president and CEO of Zevra Therapeutics, discusses the rare lysosomal storage disorder Niemann-Pick disease type C, the FDA’s upcoming decision on whether to approve the drug, and its broader efforts to build itself into a rare disease therapeutics company. Global Genes
Zevra Therapeutics, formerly KemPharm, rebranded itself in early 2023 following the acquisition of the experimental therapy arimoclomol […]
Mati Gill, CEO of AION Labs, sits down with Amar Drawid, Ph.D. to discuss how the AI venture studio works with its Big Pharma partners to define the biggest drug development hurdles the industry faces; and how it holds challenges to attract academics, entrepreneurs, and life sciences professionals with the best solutions to build new companies. development
An audio only version is available at https://lsdna.podbean.com/e/a-venture-studio-with-big-pharma-backing-seeks-to-fix-drug-development-with-ai/ or your preferred podcast platform.
https://www.youtube.com/watch?v=oO6SEg66JX4&ab_channel=LifeSciencesDNAPodcast
Mati Gill, CEO of AION Labs, sits down with Amar Drawid to discuss how the AI venture studio works with its Big Pharma partners to define the biggest drug development hurdles the industry faces; and how it holds challenges to attract academics, entrepreneurs, and life sciences professionals with the...
Michael Kelly, CEO of NervGen Pharma Corp, discusses the potential for using therapies designed to allow the nervous system to repair itself, how the company’s lead experimental candidate for spinal cord injury works, and why the same approach holds promise in treating neurodegenerative diseases.
https://thebioreport.podbean.com/e/enabling-the-nervous-system-to-repair-itself/
Giles Platford, president of the Plasma-Derived Therapies Business Unit at Takeda, discusses its work in plasma-derived therapies, its recently approved therapy for the rare neuromuscular condition CIDP, and what issues need to be addressed to ensure an adequate supply of human plasma for therapeutic applications. Global Genes
For certain rare diseases, therapies derived from human plasma, the largest component of blood, represent critical lifesaving and life-sustaining medicines. In many cases, it may represent the only therapeutic option. Takeda pharmaceutical’s Plasma-Derived Therapies Business Unit works across immu...
John Dunlop, chief scientific officer of Aliada Therapeutics, discusses its platform technology, its origins at Johnson & Johnson’s Janssen, and the company’s partnering strategy for leveraging the technology.
https://thebioreport.podbean.com/e/overcoming-barriers-to-delivering-large-molecules-to-the-brain/
Here's what you May have missed in May from The Bio Report, RARECast, Life Sciences D'n'A, and more.
Noam Solomon, co-founder and CEO of Immunai, sits down with Amar Drawid, Ph.D. to discuss how the company is using machine learning to take a multi-omics approach to understanding the complexities of the immune system, how it is constructing an atlas of immune cells, and how it is leveraging this to develop the next generation of immunomodulatory drugs.
, ,
Noam Solomon, co-founder and CEO of Immunai, sits down with Amar Drawid to discuss how the company is using machine learning to take a multi-omics approach t...
Samuel Murphy, CEO of Salubris Biotherapeutics, discusses the challenges of pursuing complex diseases with complex therapies, its pipeline, and how its China-based parent has provided it financial freedom from the vagaries of the capital markets.
https://thebioreport.podbean.com/e/developing-complex-therapies-to-tackle-complex-diseases/
Steve Roberds, chief scientific officer of the TSC Alliance, discusses the organization's success with crafting a research agenda, how it’s been able to invest in ways that catalyze research, and what it’s done to facilitate drug development by industry. Global Genes
Steve Roberds, chief scientific officer of the TSC Alliance, discusses the organization's success with crafting a research agenda, how it’s been able to invest in ways that catalyze research, and what it’s done to facilitate drug development by industry.
John Lewis, founder and CEO of Aegis Life, Inc., discusses the global need to address infectious diseases, the company’s platform technology, and how it is leveraging that to address the barriers to the delivery of vaccines and antibody therapies in developing economies.
https://thebioreport.podbean.com/e/how-solving-a-problem-with-genetic-medicines-may-solve-another-with-infectious-diseases/
Sunitha Malepati, founder of the Buffalo Initiative, discusses how she grew frustrated with the drug development landscape, how the Buffalo Initiative plans to fund patient advocacy organizations drug development efforts, and what the initiative is doing to reduce the time and cost of developing a therapy. Global Genes
Sunitha Malepati entered the world of patient advocacy after her child was diagnosed with a rare, neurodevelopmental disorder. More recently she founded the Buffalo Initiative to change drug discovery and development by creating a fund to invest in scientific enterprises driven by patient organizati...
Jay Hartenbach, chief operating officer of Diakonos Oncology, discusses the company’s dendritic cell cancer vaccine technology, how it is designed to trigger a robust immune response by tricking the immune system into recognizing cancer cells as being virally infected, and why its lead indication is an aggressive form of brain cancer.
https://thebioreport.podbean.com/e/boosting-the-power-of-dendritic-cancer-vaccines/
Frederic Revah, CEO of the non-profit Genethon, discusses the limits of licensing out its discoveries to biopharma, the different development strategies it pursues, and how it determines the best path for a particular development program. Global Genes
https://globalgenes.org/raredaily/a-gene-therapy-developer-that-embraces-different-models-for-reaching-patients/
Behavioral health is one area of medicine that has lagged in the move towards precision medicine, in part because of a lack of high-quality evidence to drive decision-making. Holmusk is working to change that by using AI and real-world data to transform mental health care. Eze Abosi, chief growth officer for Holmusk, sits down with Amar Drawid to discuss the need for standardized ways to measure symptoms for behavioral health conditions. They talk about how Holmusk is unlocking much-needed evidence to guide the successful development of new therapies, how its platform technology works, and why he believes it is charting a path for bringing precision medicines to people with mental health conditions.
Behavioral health is one area of medicine that has lagged in the move towards precision medicine, in part because of a lack of high-quality evidence to drive...
James Porter, CEO of Nuvalent, Inc., discusses how the company designs drugs that address the challenges of both kinase resistance and selectivity, its pipeline in development, and why it’s critical that its experimental therapy for non-small cell lung cancer can pe*****te the brain.
https://thebioreport.podbean.com/e/overcoming-resistance-in-cancer-with-chemistry/
Two sizable acquisitions marked an otherwise slow April for rare disease focused therapeutics financings and deals, with total potential M&A deals value up more than 300 percent year-to-date compared to the same period in 2003, according to data from DealForma and Global Genes. Marie Daghlian crunches the numbers.
Two sizable acquisitions marked an otherwise slow April for rare disease focused therapeutics financings and deals, with total potential M&A deals value year-to-date up more than 300 percent compared to the same period in 2003, according to data from Dealforma and Global Genes.
Alan H. Cohen, MD, senior vice president of clinical development and therapeutic area head of pulmonology for 4D Molecular Therapeutics, discusses the limitations of existing vectors for genetic medicines, 4DMT’s directed evolution platform technology, and its programs in cystic fibrosis and Fabry disease. Global Genes
Much of the challenge of developing genetic medicines lies in having the right vector to deliver the therapy to the cells within the body where they need to go. 4D Molecular Therapeutics has developed platform technology that generates large numbers of genetically diverse, synthetic adeno-associated...
Bobby Azamian, CEO of Tarsus Pharmaceuticals, Inc., discusses Lyme disease, the case for the company’s experimental prophylactic drug TP-05, and why you may already have been using a form of the drug to protect a four-legged member of your household.
https://thebioreport.podbean.com/e/teaching-an-old-drug-a-new-trick-to-prevent-lyme-disease/
Here's what you may have missed in April from The Bio Report, RARECast, Life Sciences D'n'A, and more.
https://www.linkedin.com/pulse/til-therapies-transomics-questions-value-daniel-levine-iemqc/?trackingId=qChH3BiBRXOgXYrftBvoOA%3D%3D
Doron Behar, co-founder and CEO of Igentify, discusses the company’s AI-powered Digital Genetic Assistant, how it works, and why it will allow genetic counselors to handle a much larger volume of patients. Global Genes
As genetic testing continues to expand, it is bringing into focus a shortage of genetic counselors who can work with patients to explain results and answer questions. Igentify is helping genetic counselors manage more patients by providing an AI-based platform that can take some of the load off of t...
Healthtech and AI Executive Advisor Christian Hein sits down with Amar Drawid, Ph.D. to discuss the use of generative AI in the life sciences, its transformational potential, and the current challenges that need to be addressed. An audio only version is available at https://lsdna.podbean.com/e/the-power-and-peril-of-generative-ai-in-biopharma-and-healthcare/
https://www.youtube.com/watch?v=VRuGN0q4Fns&ab_channel=LifeSciencesDNAPodcast
Healthtech and AI Executive Advisor Christian Hein sits down with Amar Drawid to discuss the use of generative AI in the life sciences, its transformational ...
Jason Bock, CEO of CTMC / A joint venture between Resilience + MD Anderson Cancer Center, discusses the emerging area of TIL therapies, the significance of the first approved therapy in the class, and how they may address existing limitations of CAR-T therapies.
https://thebioreport.podbean.com/e/a-new-class-of-cell-therapies-to-target-solid-tumors/
Frank Gleeson, co-founder and CEO of Satellos Bioscience, discusses its regenerative therapy for Duchenne, how it works, and why it may provide benefits to patients with other conditions that result in muscle degeneration. Global Genes
Duchenne muscular dystrophy is an inherited disease caused by genetic mutations that no longer allow the dystrophin protein to function properly. It turns out that dystrophin not only plays a role in muscle fiber, but in muscle stem cells as well and is critical for regeneration of muscle tissue. Wi...
Donald Wyatt, chief business officer for HighField Biopharmaceuticals, discusses the tumor microenvironment, HighField’s platform technology, and how it is developing lipid-based medicines to overcome challenges of existing immunotherapies.
https://thebioreport.podbean.com/e/targeting-the-tumor-microenvironment-with-lipid-based-immunotherapies/
Courtney Silverthorn, vice president of strategic alliances and innovation for the Foundation for the National Institutes of Health; and Sharon King, manager of advocacy and community engagement for Aldevronon and founder and president of Taylor's Tale: Fighting Batten Disease; discuss the Bespoke Gene Therapy Consortium, the publication of its first playbook, and how it will help gene therapy developers get their medicines to patients faster.
Global Genes
The Bespoke Gene Therapy Consortium, a public-private partnership backed by the Foundation for the National Institutes of Health, in February published its first playbook. The playbook provides a roadmap for streamlining product development and navigation of the regulatory pathway for AAV gene thera...
Samantha Dale Strasser, co-founder and chief scientific officer of Bio, sits down with Amar Drawid, Ph.D. to discuss how her company is leveraging AI to get a deeper understanding of disease biology through the use of transomics. We spoke to Strasser about the challenges studying complex diseases, why it’s critical to have the right data to separate signal from noise, and Pepper Bio's dual strategy for balancing partnerships with its own development pipeline.
Samantha Dale Strasser, co-founder and chief scientific officer of Pepper Bio, sits down with Amar Drawid to discuss how her company is leveraging AI to get ...
Jeremiah Robison, CEO of Cionic, discusses the company’s Neural sleeve, how functional electronical stimulation helps people with movement disorders walk, and how the use of adaptive algorithms continuously optimizes the stimulation it delivers.
https://thebioreport.podbean.com/e/a-company-born-from-a-father-who-wore-his-heart-on-his-sleeve/
Companies developing drugs for rare diseases raised substantial new capital so far this year, as rare disease focused public equity and debt financings reached $7.1 billion in the first quarter of 2024, up 307 percent from the $1.8 billion raised in the first quarter of 2023, according to data from DealForma and Global Genes. Marie Daghlian crunches the numbers.
Companies developing drugs for rare diseases raised substantial new capital during the first quarter of 2024, as rare disease focused public equity and debt financings reached $7.1 billion in the first quarter of 2024, up 307 percent from the $3.2 billion raised in the first quarter of 2023, accordi...
Rick Chapman, chief scientific officer of the Innovation and Value Initiativee Initiative, discusses the challenges of assessing the value of rare disease therapies, the role qualitative data should play in value assessments, and the recommendations from the report. Global Genes
The small patient populations of rare diseases, the limited natural history of these conditions, and the lack […]
CA
Be the first to know and let us send you an email when Levine Media Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Want your business to be the top-listed Media Company?
